ANAPTYSBIO, INC
ANAPTYSBIO, INC (ANAB): 12 pipeline candidates · 1 upcoming catalyst · ~34 mo cash runway · 9 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
34.0 months
0% dilution
Lead: BLA Filed
12 candidates
1 upcoming, next in ~285d
0 buys · 35 sells (180d)
A transparent, data-derived signal for ANAPTYSBIO, INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.7B
Cash
$248.5M
Quarterly Burn
$25.9M
Runway
34.0 mo
Revenue
$25.6M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| ANB032 | Phase 2 |
| ANB033 | Phase 1 |
| ANB101 | Phase 1 |
| Belrestotug | Phase 1 |
| cobolimab | Phase 3 |
| Dostarlimab | Phase 3 |
| Dostarlimab and TSR-022 | Phase 3 |
| etokimab | Phase 2 |
| GSK6097608 | Phase 1 |
| imsidolimab | BLA Filed |
Showing 10 of 12 candidates. Sign up for full pipeline.
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
204
Total value held
$1.14B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,706,302 | $94.6M |
| blackrock, inc. | 1,681,380 | $93.2M |
| tang capital management llc | 1,330,879 | $73.8M |
| morgan stanley | 993,905 | $55.1M |
| state street corp | 992,445 | $55.0M |
| affinity asset advisors, llc | 940,000 | $52.1M |
| woodline partners lp | 688,512 | $38.2M |
| palo alto investors lp | 638,161 | $35.4M |
| 683 capital management, llc | 625,000 | $34.7M |
| d. e. shaw & co., inc. | 579,296 | $32.1M |
Showing top 10 of 204 institutional holders of ANAPTYSBIO, INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in ANAPTYSBIO, INC's pipeline?
ANAPTYSBIO, INC (ANAB) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ANAPTYSBIO, INC's lead drug candidate?
ANAPTYSBIO, INC's most advanced tracked candidate is ANB032 (Phase 2) for moderate-to-severe atopic dermatitis.
What is ANAPTYSBIO, INC's next catalyst?
ANAPTYSBIO, INC's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlima" — expected March 30, 2027.
What is ANAPTYSBIO, INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ANAPTYSBIO, INC has approximately 34.0 months of cash runway.
What is ANAPTYSBIO, INC's market capitalization?
ANAPTYSBIO, INC's market capitalization is approximately $1.7B.
Get the full picture on ANAPTYSBIO, INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.